12
Hanmi Pharm
128940.KS·KRXSeoul KRFounded 19733,500 employees
Mid CappharmaPublicMetabolicOncology
Platform: LAPS Platform
Market Cap
$2.5B
All Drugs
3
Clinical Trials
5
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (128940.KS)
Loading 128940.KS stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Lisozumab | 128-3370 | Phase 2/3 | 2 | Menin | Endometrial CaAS | ||
| Datozanubrutinib | 128-7338 | Phase 2 | 2 | CGRP | Hemophilia A | ||
| Mirimavacamten | 128-7965 | Phase 1/2 | 1 | PI3Kα | Bladder Ca |
SEC Filings & Financial Documents
SEC filings are not available for KRX-listed companies.
Hanmi Pharm trades on KRX (KR). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (3)